Dose-Dense Chemotherapy Plus Bevacizumab in High Risk Lymph Node Positive Breast Cancer: A Pilot Study

Part of paid clinical trials in Santa Monica, California.

Sponsor
Chap, Linnea I., M.D.
Study ID
NCT00378638
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This research focuses on women with breast cancer whose disease has not significantly progressed, but who have 5 or more lymph nodes involved. In this study subjects will receive bevacizumab, a drug which is FDA approved for colon cancer but not for breast cancer, in combination with a regimen of approved chemotherapy drugs known as "dose dense chemotherapy." The study will observe the effectiveness and tolerability of this regimen.

Key Dates

First listed
Sep 20, 2006
Start date
Jun 30, 2006
Status verified
Oct 2007
Completion
Oct 31, 2008

Study Design

Enrollment
30 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Incidence of treatment failure, 2 and 5 year Disease Free Survival.

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Premiere OncologySanta MonicaCalifornia90404
Linnea I. Chap, M.D.
[email protected]
310-633-8400
Marilyn Mulay, MSN
[email protected]
(310) 633-8400
Linnea I. Chap, M.D. (PRINCIPAL_INVESTIGATOR)

Find similar trials in Santa Monica, CA

By condition
Breast cancer
By specialty
OncologyBreast oncologyWomen's health
By research site
Premiere Oncology· Santa Monica, CA

Related Studies